Inactivated whole-cell bacterial vaccines: current status and novel strategies.
Inactivated bacterial whole-cell vaccines have been the most widely studied prophylactic treatment for infectious diseases. They offer an economical, and potentially safe, effective means of preventing disease. The disadvantages of these vaccines have been that parenteral administration, while effective in some instances, may have caused adverse reactions in vaccinees, while oral administration often required high doses and resulted in short-term immunity. More recent studies describing new approaches for improving antigenicity of inactivated whole-cell vaccines and the enhancement of immune responses to oral immunization offer great hope for improving the efficacy of these agents. Promising whole cell vaccines include those against Vibrio cholerae, enterotoxigenic Escherichia coli, and more recently Campylobacter jejuni.
Antex Biologics Inc., Gaithersburg, MD 20879, USA.
J L
JL
Pace
H A
HA
Rossi
V M
VM
Esposito
S M
SM
Frey
K D
KD
Tucker
R I
RI
Walker
D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use
D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated